Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18596899 | 0.86 | KCNH2 (0.41) | HRH1KCNH2 | |
| SCHEMBL19003563 | 0.78 | HTT (0.42) | — | |
| SCHEMBL23717412 | 0.77 | ADRB1 (0.50) | — | |
| SCHEMBL25440572 | 0.75 | KCNH2 (0.37) | HRH1KCNB1KCNH2 | |
| SCHEMBL12891857 | 0.74 | HRH1 (0.38) | HRH1KCNB1MAPT | |
| SCHEMBL8297992 | 0.74 | HRH1 (0.38) | HRH1KCNB1MAPT | |
| SCHEMBL12891853 | 0.74 | HRH1 (0.38) | HRH1KCNB1MAPT | |
| SCHEMBL21078223 | 0.74 | NCF1 (0.35) | KCNH2 | |
| SCHEMBL2759108 | 0.73 | HRH1 (0.38) | HRH1KCNB1MAPT | |
| SCHEMBL26217680 | 0.72 | SLC6A4 (0.36) | MAPTCYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK6, MAPK1, MAPK8 | HRH1 1269/4885KCNB1 2333/4885MAPT 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.